Autopsy report · NCT06544642

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

“Company's strategic decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 116 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Astellas Pharma Global Development, Inc.

Sponsor type

Industry

Conditions

Healthy Volunteers; Sjögren's Syndrome

Interventions

ASP5502; Placebo

Participants

116

Sites

1

Countries

United States

Trials that died the same way

• Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma
  “Strategic corporate decision” (94% match in meaning)
• CT 327 in the "Atopy Patch Test" Model
  “Strategic decision” (90% match in meaning)
• Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test
  “Business Strategic Decision” (89% match in meaning)
• Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
  “Strategic business decision” (89% match in meaning)
• Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
  “Company Strategy” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.